Welcome to Insider Trades Daily, glad you're here! Every day, more than 500,000 investors use this newsletter to track insider buying and selling across major public companies. It’s a simple way to see what the people closest to the business are doing with their own money. Before we start sending your daily updates, there’s just one quick thing left to do. Please confirm your subscription using the link below. Click Here to Confirm Your Subscription to Insider Trades Daily It takes a few seconds and helps make sure your newsletter shows up where it belongs, your inbox, not a spam folder. Once you’re confirmed, we’ll take it from there and deliver clear, no-nonsense insider trading insights straight to you. Start Receiving Insider Information The InsiderTrades.com Team P.S. If there's anything we can do to improve your experience, please let us know by replying to this email.
Additional Reading from MarketBeat
3 Biotech Stocks That Could Benefit from the Patent CliffAuthored by Chris Markoch. Article Posted: 4/27/2026. 
Key Points
- Biotech M&A activity is accelerating ahead of a projected $300 billion patent cliff, creating new opportunities in smaller, innovative companies.
- Gene editing leaders like CRISPR Therapeutics, Intellia Therapeutics, and Beam Therapeutics offer differentiated platforms that could attract acquisition interest.
- Investors willing to take on higher risk may find outsized upside in biotech stocks developing one-time curative therapies for chronic diseases.
- Special Report: Elon’s “Hidden” Company
Biotechnology stocks have seen a spike in merger and acquisition (M&A) activity. In March 2026 alone, there were 10 deals valued at approximately $31.5 billion. A key reason for this activity is the upcoming patent cliff: the period when a drug loses its exclusive status and faces biosimilar competition. Analysts forecast the industry faces a $300 billion patent cliff by 2030.
When the SpaceX IPO launches, most retail investors will be locked out. The banks, funds, and insiders get in early - while everyone else waits on the sidelines.
But one small infrastructure supplier - a critical piece Musk can't scale the Colossus network without - is still trading well under institutional radar. A new briefing reveals the name and ticker at no cost. Get the SpaceX infrastructure stock name and ticker here
Two large-cap biopharma companies with best-selling drugs approaching the cliff are Merck & Co. (NYSE: MRK) with Keytruda and Bristol Myers Squibb (NYSE: BMY) with Eliquis. These remain quality names that offer investors the relative safety of strong balance sheets and dividends. There is also an opportunity for investors with a higher risk tolerance: companies that could become acquisition targets. These are firms developing therapies that could shift care from chronic management to one-time cures. Acquirable Assets: Which Biotechs Deserve a Higher FloorWhile stocks in a sector often move together, biotech requires a qualifier: the most attractive companies are those with acquirable assets. Investors should look for three things:
The underlying science is differentiated enough that a large-cap company can’t quickly replicate it. The company owns or controls its intellectual property. The drug or therapeutic has an indication large enough to move revenue and earnings for the acquiring company. Many small-cap biotech names don’t meet every criterion, which is one reason this is a tricky sector for investors. Still, there are three companies worth watching; each sits at a different point on the risk/maturity curve. This isn’t a prediction that these companies will be acquired, but they check the three boxes above and offer the potential for one-time cures of chronic or hard-to-treat diseases. First-Mover Advantage in Gene EditingGene editing is a paradigm-shifting opportunity, and CRISPR Therapeutics (NASDAQ: CRSP) is an established pure play in the space. Unlike many peers, CRISPR already has a commercial product: CASGEVY generated over $100 million in revenue in 2025, and patient initiations have nearly tripled year over year. CASGEVY treats sickle cell disease (SCD) and beta-thalassemia—large but relatively niche markets. A key growth vector for CRSP is its work in cardiovascular disease. The company’s CTX310 candidate is being developed as a potential one-and-done option to rapidly lower triglyceride and LDL levels. CTX310 recently delivered positive Phase 1 data, which is an encouraging early signal, though there is still a runway to commercial approval. Analysts are generally bullish on CRSP, but of the 19 analysts tracked by MarketBeat, two rate the stock a Sell. Short interest is also around 24% as of this writing, so investors may want to scale into a position and use dips to add exposure. High-Risk, High-Reward In Vivo EditingIf CRISPR Therapeutics represents the most commercially mature name in gene editing, Intellia Therapeutics (NASDAQ: NTLA) represents the highest-stakes bet. Intellia is a pioneer of in vivo CRISPR editing—making therapeutic edits directly inside the body rather than ex vivo. That distinction matters because it dramatically expands the range of diseases gene editing can target. Intellia’s two late-stage candidates are nexiguran ziclumeran (nex-z), developed with Regeneron for transthyretin amyloidosis (ATTR), and lonvoguran ziclumeran (lonvo-z), a wholly owned program for hereditary angioedema (HAE). Both target rare, underserved diseases where a one-time functional cure would be a meaningful paradigm shift from chronic management. Key 2026 catalysts include a Phase 3 data readout for lonvo-z in HAE, expected April 27, 2026, and efforts to restart and advance its ATTR cardiomyopathy program after the FDA lifted a clinical hold. Either catalyst could move the stock materially in either direction. NTLA is not for the faint of heart, but for investors who believe in the in vivo thesis, it is the purest expression of that approach. Precision Gene Editing’s Next FrontierWhere Intellia focuses on CRISPR-Cas9, Beam Therapeutics (NASDAQ: BEAM) is developing a more precise approach. Its base editing technology works like a molecular pencil—rewriting a single genetic letter rather than making a double-strand cut. That precision could address persistent safety concerns that have kept some investors on the sidelines. Beam's most advanced wholly owned program, BEAM-302, targets alpha-1 antitrypsin deficiency (AATD), a genetic disorder affecting the lungs and liver that currently has no curative treatment. In March 2026, the company reported positive updated Phase 1/2 data and announced plans to advance BEAM-302 into pivotal testing in the second half of the year. Its sickle cell program, risto-cel, could see a U.S. approval filing as early as late 2026. Beam carries more early-stage risk than CRSP and faces near-term funding questions because its cash runway is limited. But its differentiated platform and proximity to pivotal data make it worth monitoring for investors willing to accept that risk in exchange for the upside a successful readout or acquisition offer could deliver. |
0 Response to "Follow the money"
Post a Comment